These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 17393074)
1. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. van Vlerken LE; Vyas TK; Amiji MM Pharm Res; 2007 Aug; 24(8):1405-14. PubMed ID: 17393074 [TBL] [Abstract][Full Text] [Related]
2. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Shenoy D; Little S; Langer R; Amiji M Pharm Res; 2005 Dec; 22(12):2107-14. PubMed ID: 16254763 [TBL] [Abstract][Full Text] [Related]
3. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723 [TBL] [Abstract][Full Text] [Related]
4. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688 [TBL] [Abstract][Full Text] [Related]
5. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification. Zhang S; Tang C; Yin C Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373 [TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
7. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin. Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505 [TBL] [Abstract][Full Text] [Related]
8. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Shenoy DB; Amiji MM Int J Pharm; 2005 Apr; 293(1-2):261-70. PubMed ID: 15778064 [TBL] [Abstract][Full Text] [Related]
9. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo. Du XJ; Wang JL; Liu WW; Yang JX; Sun CY; Sun R; Li HJ; Shen S; Luo YL; Ye XD; Zhu YH; Yang XZ; Wang J Biomaterials; 2015 Nov; 69():1-11. PubMed ID: 26275857 [TBL] [Abstract][Full Text] [Related]
10. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Hadinoto K; Sundaresan A; Cheow WS Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180 [TBL] [Abstract][Full Text] [Related]
11. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411 [TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol) amphiphilic copolymer for anticancer drugs delivery. Feng R; Zhu W; Teng F; Liu N; Yang F; Meng N; Song Z Anticancer Agents Med Chem; 2015; 15(2):176-88. PubMed ID: 25420636 [TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Shenoy D; Little S; Langer R; Amiji M Mol Pharm; 2005; 2(5):357-66. PubMed ID: 16196488 [TBL] [Abstract][Full Text] [Related]
15. Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy. Sun L; Wu Q; Peng F; Liu L; Gong C Colloids Surf B Biointerfaces; 2015 Nov; 135():56-72. PubMed ID: 26241917 [TBL] [Abstract][Full Text] [Related]
16. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma. Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660 [TBL] [Abstract][Full Text] [Related]
17. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related]
18. Carbon nanotubes for delivery of small molecule drugs. Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402 [TBL] [Abstract][Full Text] [Related]